Condition: Tenosynovial Giant Cell Tumor · Sponsor: Deciphera Pharmaceuticals, LLC
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
This description comes directly from the study's public registry record.
Clinical Team · 888-724-3274 · clinicaltrials@deciphera.com
Always discuss trial participation with your own doctor first.
| Synexus Clinical Research, US INC | Wilmington, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07075471